MedPath

European Organisation For Research & Treatment Of Cancer

🇬🇧United Kingdom
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.eortc.be

Infliximab in Treating Patients With Myelodysplastic Syndrome

Phase 2
Completed
Conditions
Myelodysplastic Syndromes
First Posted Date
2003-12-11
Last Posted Date
2012-07-16
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
46
Registration Number
NCT00074074
Locations
🇨🇿

Institute of Hematology and Blood Transfusion, Prague, Czech Republic

🇳🇱

Ziekenhuis Bronovo, Den Haag, Netherlands

🇧🇪

AZ Sint-Jan, Brugge, Belgium

and more 16 locations

Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides

Phase 2
Completed
Conditions
Lymphoma
Interventions
First Posted Date
2003-12-11
Last Posted Date
2018-07-09
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
49
Registration Number
NCT00074087
Locations
🇦🇹

Karl-Franzens-University Graz, Graz, Austria

🇬🇧

St. Thomas' Hospital, London, England, United Kingdom

🇦🇹

Allgemeines Krankenhaus - Universitatskliniken, Vienna, Austria

and more 8 locations

Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia

Phase 2
Terminated
Conditions
Leukemia
First Posted Date
2003-12-10
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
13
Registration Number
NCT00003729
Locations
🇧🇪

Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels (Bruxelles), Belgium

🇧🇪

U.Z. Gasthuisberg, Leuven, Belgium

🇧🇪

Universitair Ziekenhuis Gent, Ghent (Gent), Belgium

and more 20 locations

Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Phase 3
Conditions
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
First Posted Date
2003-11-25
Last Posted Date
2009-02-09
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
207
Registration Number
NCT00002989
Locations
🇮🇹

Ospedale San Eugenio, Rome, Italy

🇧🇪

Institut Jules Bordet, Brussels (Bruxelles), Belgium

🇩🇪

Eberhard Karls Universitaet, Tuebingen, Germany

and more 6 locations

Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy

Phase 2
Terminated
Conditions
Breast Cancer
First Posted Date
2003-10-08
Last Posted Date
2012-07-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
18
Registration Number
NCT00006121
Locations
🇮🇱

Rambam Medical Center, Haifa, Israel

🇦🇹

Kaiser Franz Josef Hospital, Vienna (Wien), Austria

🇧🇪

Institut Jules Bordet, Brussels (Bruxelles), Belgium

and more 7 locations

MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
First Posted Date
2003-10-01
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
30
Registration Number
NCT00004886
Locations
🇫🇷

Centre Oscar Lambret, Lille, France

🇫🇷

Institut Curie - Section Medicale, Paris, France

🇩🇪

Haemato-Onkologische Praxis und Tagesklinik, Munich (Muenchen), Germany

Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer

Phase 2
Terminated
Conditions
Anal Cancer
First Posted Date
2003-09-11
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
88
Registration Number
NCT00068744
Locations
🇷🇸

Institute of Oncology and Radiology of Serbia, Belgrade, Serbia

🇧🇪

Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium

🇧🇪

Cazk Groeninghe - Campus Maria's Voorzienigheid, Kortrijk, Belgium

and more 21 locations

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
First Posted Date
2003-09-11
Last Posted Date
2012-09-12
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
23
Registration Number
NCT00068757
Locations
🇳🇱

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

🇧🇪

Institut Jules Bordet, Brussels, Belgium

🇫🇷

Institut Curie Hopital, Paris, France

Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2003-08-07
Last Posted Date
2013-10-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
71
Registration Number
NCT00066378
Locations
🇧🇪

Institut Jules Bordet, Brussels, Belgium

🇧🇪

Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium

🇧🇪

Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium

and more 6 locations

Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer

Phase 2
Completed
Conditions
Penile Cancer
First Posted Date
2003-08-07
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT00066391
Locations
🇬🇧

Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom

🇧🇪

U.Z. Gasthuisberg, Leuven, Belgium

🇭🇺

National Institute of Oncology, Budapest, Hungary

and more 5 locations
© Copyright 2025. All Rights Reserved by MedPath